European Union - English - EMA (European Medicines Agency)

emdoka bvba - meloxicam - oxicams - horses; pigs; cattle - cattlefor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs. for use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. for adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.pigsfor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation. for adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitits-metritis-agalactia syndrome) with appropriate antibiotic therapy.horsesfor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders. for the relief of pain associated with equine colic.dogs: alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.cats:reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.

European Union - English - EMA (European Medicines Agency)

emdoka bvba - halofuginone lactate - halofuginone, other antiprotozoal agents - calves, newborn - in newborn calves:prevention of diarrhoea due to diagnosed cryptosporidium parvum infection, in farms with history of cryptosporidiosis. administration should start in the first 24 to 48 hours of age.reduction of diarrhoea due to diagnosed cryptosporidium parvum infection. administration should start within 24 hours after the onset of diarrhoea. in both cases, the reduction of oocysts excretion has been demonstrated.

Israel - English - Ministry of Health

raz pharmaceutics ltd, israel - benzydamine hydrochloride - mouthwash - benzydamine hydrochloride 0.15 %w/v - benzydamine - locally acting analgesic and anti-inflammatory treatment for the relief of painful inflammatory conditions of the mouth and throat influding: traumatic conditions : pharyngitis following tonsillectomy or the use of a naso-gastric tube .inflammatory conditions : pharyngitis, aphthous ulcers and oral ulceration due to radiation therapy. dentistry : for use after dental operations.

Singapore - English - HSA (Health Sciences Authority)

dch auriga singapore - iomeprol eqv iodine - injection - 300 mg/ml - iomeprol eqv iodine 300 mg/ml

Singapore - English - HSA (Health Sciences Authority)

dch auriga singapore - iomeprol eqv iodine - injection - 350 mg/ml - iomeprol eqv iodine 350 mg/ml

Singapore - English - HSA (Health Sciences Authority)

dch auriga singapore - iomeprol eqv iodine - injection - 400 mg/ml - iomeprol eqv iodine 400 mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

medtronic australasia pty ltd - 46425 - bone matrix implant, animal-derived, bioabsorbable - mastergraft? putty is supplied as a sterile, dry, solid, construct that is hydrated for single patient use and is a mouldable form of bone void filler. mastergraft? products are biocompatible, osteoconductive, porous implants that allows for bony in growth across the graft site while resorbing at a rate consistent with bone healing. mastergraft? putty is intended to help fill voids or gaps in bone, which may be surgically created osseous defects, or osseous defects caused by traumatic injury to the bone. mastergraft? putty provides a bone void filler that is resorbed and is replaced with bone during the natural healing process. the putty when combined with either autogenous bone marrow, and/or sterile water, and/or autograft is indicated as a bone void filler for bony voids or gaps that are not intrinsic to the stability of the bony structure. additionally, mastergraft putty can be used with autograft as a bone extender. specific indications for use include oral/maxillofacial augmentation or reconstruction.

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - promethazine hydrochloride - solution for injection - 2.5 %w/v